Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: Predictors of outcome

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Adenis, Antoine ^a,b   Tresch, Emmanuelle ^a   Dewas, Sylvain ^a,c   Romano, Olivier ^a   Messager, Mathieu ^d   Amela, Eric ^a   Clisant, Stéphanie ^a   Kramar, Andrew ^a   Mariette, Christophe ^c,d   Mirabel, Xavier ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^c UNIV LILLE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Chemoradiotherapy; Oesophageal cancer; Prognosis; Radiation therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; NAVELBINE;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DYSPHAGIA; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84883533681     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-413     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Faivre J, Forman D, Estève J, Obradovic M, Gatta G. Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer 1998, 34:2167-2175. 10.1016/S0959-8049(98)00329-3, 10070283.
3. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007, 8:545-553. 10.1016/S1470-2045(07)70172-9, 17540306.
4. Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008, 247:365-371. 10.1097/SLA.0b013e31815aaadf, 18216546.
5. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326:1593-1598. 10.1056/NEJM199206113262403, 1584260.
6. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01): radiation therapy oncology group. JAMA 1999, 281:1623-1627. 10.1001/jama.281.17.1623, 10235156.
7. Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotté P, Lerebours E, Michel P. Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007, 102:2557-2563. 10.1111/j.1572-0241.2007.01437.x, 17680847.
8. Lim JT, Truong PT, Berthelet E, Pai H, Joe H, Wai E, Larsson S, Kader HA, Weinerman B, Wilson K, Olivotto IA. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003, 57:1328-1335. 10.1016/S0360-3016(03)00751-X, 14630270.
9. Tahara M, Ohtsu A, Hironaka S, Ku N, Ishikura S, Miyata Y, Ogino T, Yoshida S. Clinical impact of criteria for complete response of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005, 35:316-623. 10.1093/jjco/hyi095, 15961436.
10. Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, Mirabel X, Hamidou H, Raoul JL, Jacob JH, Hellot MF, Prod'homme S, Paillot B. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer 2006, 95:705-709. 10.1038/sj.bjc.6603328, 2360517, 16967056.
11. Conroy T, Yataghene Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B, Rio E, Le Prisé E, Peiffert D, Adenis A. Phase II randomized trial of definitive chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in first line treatment of patients with inoperable esophageal cancer. Br J Cancer 2010, 103:1349-1355. 10.1038/sj.bjc.6605943, 2990616, 20940718.
12. Brown WA, Thomas J, Gotley D, Burmeister BH, Lim KH, Martin I, Walpole ET, Thomson DB, Harvey JA, Smithers BM. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 2004, 91:199-204. 10.1002/bjs.4411, 14760668.
13. Kalha I, Kaw M, Fukami N, Patel M, Singh S, Gagneja H, Cohen D, Morris J. The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer 2004, 101:940-947. 10.1002/cncr.20429, 15329901.
14. Westerterp M, van Westreenen HL, Reitsma JB, R Ansari H, Kasza K, Szeto L, Vokes EE. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy -systematic review. Radiology 2005, 236:841-851. 10.1148/radiol.2363041042, 16118165.
15. Triboulet JP, Amrouni H, Guillem P, Vandenhaute B, Lecomte-Houcke M, Adenis A. Long term results of esophageal epidermoïd cancer with complete remeission to preoperative chemoradiotherapy. Ann Chir 1998, 52:503-508.
16. Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 2008, 248:902-908. 10.1097/SLA.0b013e31818f3afb, 19092334.
17. Sarkaria IS, Rizk NP, Bains MS, Tang LH, Ilson DH, Minsky BI, Rusch VW. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg 2009, 249:764-767. 10.1097/SLA.0b013e3181a38e9e, 19387328.
18. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, Trans-Tasman Radiation Oncology Group Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 9:659-668. Trans-Tasman Radiation Oncology Group.
19. Vallböhmer D, Hölscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schröder W, Bollschweiler E, Hofstetter W. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg 2010, 252:744-749. 10.1097/SLA.0b013e3181fb8dde, 21037429.
20. Ishihara R, Yamamoto S, Iishi H, Takeuchi Y, Sugimoto N, Higashino K, Uedo N, Tatsuta M, Yano M, Imai A, Nishiyama K. Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:123-129. 10.1016/j.ijrobp.2009.01.038, 19386426.
21. Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H, Gastrointestinal oncology study group of the Japan clinical oncology group (JCOG) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2011, 81:684-690. 10.1016/j.ijrobp.2010.06.033, 20932658, Gastrointestinal oncology study group of the Japan clinical oncology group (JCOG).
22. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology 2012, 82:108-113. 10.1159/000335951, 22328056.
23. Ellis FH, Heatley GJ, Balogh K. Proposal for improved staging criteria for carcinoma of the esophagus and cardia. Eur J Cardiothorac Surg 1997, 12:361-364. 10.1016/S1010-7940(97)00178-4, 9332912.
24. Mariette C, Maurel A, Fabre S, Balon JM, Triboulet JP. Preoperative prognostic factors for squamous cell carcinoma of the thoracic esophagus. Gastroenterol Clin Biol 2001, 25:468-472.
25. O'Gilvie AL, Dronfield MW, Ferguson R, Atkinson M. Palliative intubation of esophagogastric neoplasms at fiberoptic endoscopy. Gut 1982, 23:1060-1067. 10.1136/gut.23.12.1060, 1419858, 6184269.
26. Adenis A, Francois E, Conroy T, Marchal C, Teissier E, Vedrenne B, Seitz JF, Mirabel X, Pignol JP, Resbeut M, Gyselinck N, Brandely M. Phase I study of vinorelbine and concurrent radiation for locally advanced esophageal cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 1999, 18:271.
27. Wider HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004, 2:900-908.
28. McLoughlin JM, Melis M, Seagel EM, Dean EM, Weber JM, Chern J, Elliott M, Kelley ST, Karl RC. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?. J Am Coll Surg 2008, 206:879-886. 10.1016/j.jamcollsurg.2007.12.027, 18471715.
29. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus 2004, 17:38-43. 10.1111/j.1442-2050.2004.00355.x, 15209739.
30. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174. 10.1200/JCO.20.5.1167, 11870157.
31. Crosby TDL, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 2004, 90:70-75. 10.1038/sj.bjc.6601461, 2395332, 14710209.
32. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer with definite chemoradiation. Cancer 2012, 118:2632-2640. 10.1002/cncr.26586, 3747650, 22565611.
33. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the oesophagus: FFCD 9102. J Clin Oncol 2007, 25:1160-1168. 10.1200/JCO.2005.04.7118, 17401004.
34. Jouve JL, Michel P, Mariette C, Bonnetain F, Bouché O, Conroy T, Pezet D, Burtin P, Segol P, Bedenne L. Fédération francophone de cancérologie digestive: outcome of the non randomized patients in the FFCD 9102 trial: chemo-radiation followed by surgery compared with chemo-radiation alone in squamous cancer of the esophagus: ASCO Annual Meeting Proceedings. J Clin Oncol 2008, 26:A4555.
35. Mariette C, De Botton ML, Piessen G. Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice?. Ann Surg Oncol 2012, 19:2128-2134. 10.1245/s10434-012-2225-6, 22322948.